Journal of travel medicine最新文献

{"title":"President Trump's foreign aid freeze: impact on Cambodia's tuberculosis programme.","authors":"Esabelle Lo Yan Yam, Siyan Yi","doi":"10.1093/jtm/taaf019","DOIUrl":"10.1093/jtm/taaf019","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Travel-associated international spread of Oropouche virus beyond the Amazon.","authors":"Felipe Campos de Melo Iani, Felicidade Mota Pereira, Elaine Cristina de Oliveira, Janete Taynã Nascimento Rodrigues, Mariza Hoffmann Machado, Vagner Fonseca, Talita Emile Ribeiro Adelino, Natália Rocha Guimarães, Luiz Marcelo Ribeiro Tomé, Marcela Kelly Astete Gómez, Vanessa Brandão Nardy, Adriana Aparecida Ribeiro, Alexander Rosewell, Álvaro Gil A Ferreira, Arabela Leal E Silva de Mello, Brenda Machado Moura Fernandes, Carlos Frederico Campelo de Albuquerque, Dejanira Dos Santos Pereira, Eline Carvalho Pimentel, Fábio Guilherme Mesquita Lima, Fernanda Viana Moreira Silva, Glauco de Carvalho Pereira, Houriiyah Tegally, Júlia Deffune Profeta Cidin Almeida, Keldenn Melo Farias Moreno, Klaucia Rodrigues Vasconcelos, Leandro Cavalcante Santos, Lívia Cristina Machado Silva, Livia C V Frutuoso, Ludmila Oliveira Lamounier, Mariana Araújo Costa, Marília Santini de Oliveira, Marlei Pickler Dediasi Dos Anjos, Massimo Ciccozzi, Maurício Teixeira Lima, Maira Alves Pereira, Marília Lima Cruz Rocha, Paulo Eduardo de Souza da Silva, Peter M Rabinowitz, Priscila Souza de Almeida, Richard Lessells, Ricardo T Gazzinelli, Rivaldo Venâncio da Cunha, Sabrina Gonçalves, Sara Cândida Ferreira Dos Santos, Senele Ana de Alcântara Belettini, Silvia Helena Sousa Pietra Pedroso, Sofia Isabel Rótulo Araújo, Stephanni Figueiredo da Silva, Julio Croda, Ethel Maciel, Wes Van Voorhis, Darren P Martin, Edward C Holmes, Tulio de Oliveira, José Lourenço, Luiz Carlos Junior Alcantara, Marta Giovanetti","doi":"10.1093/jtm/taaf018","DOIUrl":"10.1093/jtm/taaf018","url":null,"abstract":"<p><p>Oropouche virus (OROV), first detected in Trinidad and Tobago in 1955, was historically confined to the Brazilian Amazon Basin. However, since late 2022, an increasing number of OROV cases have been reported across various regions of Brazil as well as in urban centers in Bolivia, Ecuador, Guyana, Colombia, Cuba, Panama, and Peru. In collaboration with Central Public Health Laboratories across Brazil, we integrated epidemiological metadata with genomic analyses from recent cases, generating 133 whole-genome sequences covering the virus's three genomic segments (L, M, and S). These include the first genomes from regions outside the Amazon and from the first recorded fatal cases. Phylogenetic analyses show that the 2024 OROV genomes form a monophyletic group with sequences from the Amazon Basin sampled since 2022, revealing a rapid north-to-south viral movement into historically non-endemic areas. We identified 21 reassortment events, though it remains unclear whether these genomic changes have facilitated viral adaptation to local ecological conditions or contributed to phenotypic traits of public health significance. Our findings demonstrate how OROV has evolved through reassortment and spread rapidly across multiple states in Brazil, leading to the largest outbreak ever recorded outside the Amazon and the first confirmed fatalities. Additionally, by analysing travel-related cases, we provide the first insights into the international spread of OROV beyond Brazil, further highlighting the role of human mobility in its dissemination. The virus's recent rapid geographic expansion and the emergence of severe cases emphasize the urgent need for enhanced surveillance across the Americas. In the absence of significant human population changes over the past two years, factors such as viral adaptation, deforestation, and climate shifts-either individually or in combination-may have facilitated the spread of OROV beyond the Amazon Basin through both local and travel-associated transmission.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overseas- and locally acquired sexually transmissible infections in Australia, 2017-23.","authors":"Wondimeneh Shiferaw, Judith A Dean, Deborah Mills, Colleen L Lau, Luis Furuya-Kanamori","doi":"10.1093/jtm/taaf022","DOIUrl":"10.1093/jtm/taaf022","url":null,"abstract":"<p><strong>Introduction: </strong>International travel is a significant contributor to the acquisition of sexually transmissible infections (STIs). Despite the high volume of outbound travel from Australia, peaking at 10.8 million travellers in 2023, limited data exist on the burden of overseas-acquired STIs. This study aims to investigate the burden and trends of overseas- and locally acquired STIs in Australia.</p><p><strong>Methods: </strong>We analysed STI cases notified to Australia's National Notifiable Diseases Surveillance System (NNDSS) from January 2017 to December 2023. A comparative analysis was conducted by place of acquisition (i.e. overseas versus local), with the geographical origins of overseas-acquired cases mapped using ArcMap and temporal trends assessed across pre-COVID-19, pandemic and post-pandemic periods.</p><p><strong>Results: </strong>A total of 967 193 records were obtained from NNDSS, of which 188 788 STI cases (11 782 overseas- and 177 006 locally acquired) were included in the analysis. Males were the most affected group (63% of overseas- and 60% of locally acquired), and young adults aged 20-24 years represented a quarter of cases (24.6% of overseas- and 25.9% of locally acquired). The incidence of overseas-acquired STI cases rose nearly threefold, from 12.8 per 100 000 travellers in 2017 to 35.0 per 100 00 travellers in 2019, and then declined during the COVID-19 pandemic due to Australia's travel restrictions to 16.4 per 100 000 travellers in 2020. A surge was observed in 2021, with 46.5 per 100 000 travellers. The most common regions of acquisition were Southeast Asia (n = 2390, 44.6%), North and South America (n = 663, 12.4%) and Northwest Europe (n = 580, 10.8%).</p><p><strong>Conclusions: </strong>This study highlights the patterns of overseas- and locally acquired STIs in Australia, with chlamydia remaining the most prevalent (but declining since 2021), while gonorrhoea has been increasing, among overseas-acquired cases. Variations in the region of acquisition and demographic factors highlight the critical need for tailored safer-sex advice during pre-travel consultations, particularly for males and young adults travelling to high-prevalence destinations.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'What about my teeth?'-Tales of missing dental travel health advice.","authors":"Irmgard L Bauer","doi":"10.1093/jtm/taaf026","DOIUrl":"https://doi.org/10.1093/jtm/taaf026","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Travel to low- and middle-income countries and travellers' diarrhoea increase risk of mismatching antimicrobial therapy for urinary tract infection.","authors":"Anu Patjas, Anu Kantele","doi":"10.1093/jtm/taaf025","DOIUrl":"https://doi.org/10.1093/jtm/taaf025","url":null,"abstract":"<p><strong>Background: </strong>Travel to low- and middle-income countries (LMICs) increases the risk of urinary tract infections (UTIs), including those caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE). Focusing on international travel, we explored resistance profiles of urinary ESBL-PE and non-ESBL-PE isolates in a low antimicrobial resistance prevalence country and factors associated with UTI treatment failure.</p><p><strong>Methods: </strong>During 2015-19, we recruited 18-65-year-old individuals with recent ESBL-PE UTI and a respective cohort of those with non-ESBL-PE UTI to complete questionnaires on symptoms, antibiotic therapies, and treatment failure risk factors. We compared uropathogens' resistance profiles among patients with or without LMIC travel history and conducted multivariable analyses to identify factors contributing to mismatching antimicrobial treatment (uropathogen resistant to the initial antimicrobial used) and clinical failure.</p><p><strong>Results: </strong>Among non-ESBL-PE UTI patients (n = 187), trimethoprim resistance was more common in isolates from individuals with recent LMIC travel (8/19, 42.1%) compared to those without (30/167, 18.0%) (OR 3.3, CI95% 1.2-9.0). ESBL-PE isolates (n = 130) showed no differences in resistance profiles with respect to LMIC travel history.In the group non-ESBL-PE UTI, risk factors included microbiological mismatching recent LMIC travel (AOR 3.6, CI95% 1.0-12.7) and travellers' diarrhoea (AOR 7.1, CI95% 1.1-45.6); no factors were significantly associated with mismatching in the group ESBL-PE UTI. As risk factors for clinical failure, in the group non-ESBL-PE UTI, we identified microbiological mismatching (AOR 15.2, CI95% 4.0-57.9), and renal/bladder disease (AOR 5.2, CI95% 1.1-23.2), and in the group ESBL-PE UTI, microbiological mismatching (AOR 8.1, CI95% 2.6-24.7).</p><p><strong>Conclusions: </strong>LMIC travel increases the risk of nonmatching empiric antimicrobials, concurring with increased trimethoprim resistance rates among the non-ESBL-PE isolates. Our data suggest that UTI patients with recent LMIC travel should not be empirically treated with trimethoprim and, when possible, urinary culturing is warranted.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paracoccidioidomycosis in a Venezuelan migrant.","authors":"Leidy J Medina-Lozano, Adalberto E Lobato Ureche, José Jaramillo Osorio, Abraham Katime Zuñiga, Bertha Lacouture Ortiz, Álvaro A Faccini-Martínez","doi":"10.1093/jtm/taaf024","DOIUrl":"https://doi.org/10.1093/jtm/taaf024","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Celebrating World Neglected Tropical Diseases Day: a global call to unite, act, and eliminate Neglected Tropical Diseases.","authors":"Annika B Wilder-Smith, Lucinda C Fuller, Niraj Parajuli","doi":"10.1093/jtm/taaf007","DOIUrl":"10.1093/jtm/taaf007","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protracted Katayama syndrome in an immunocompromised traveller: the challenge of assessing cure.","authors":"Steven Van Den Broucke, Rik Schrijvers, Marjan Van Esbroeck, Jasmine Coppens, Lisette Van Lieshout, Emmanuel Bottieau","doi":"10.1093/jtm/taae149","DOIUrl":"10.1093/jtm/taae149","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults.","authors":"Deborah J Mills, Narayan Gyawali, Nirupama A Nammunige, Christine Mills, Gregor J Devine, Colleen L Lau, Luis Furuya-Kanamori","doi":"10.1093/jtm/taaf006","DOIUrl":"10.1093/jtm/taaf006","url":null,"abstract":"<p><strong>Background: </strong>Japanese encephalitis virus is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond 5 years remain limited.</p><p><strong>Methods: </strong>We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia. Participants were stratified based on the time since vaccination: 2-5 years and >5 years. Neutralizing antibody titres were measured using the plaque reduction neutralization test (PRNT50), with titres ≥10 indicating seropositivity.</p><p><strong>Results: </strong>Of the 103 participants, 47 were vaccinated 2-5 years prior and 56 were vaccinated ≥5 years prior to enrolment. All participants vaccinated within 5 years remain seropositive, whilst 52 of 56 (92.9%) vaccinated ≥5 years ago were seropositive. Four participants (7.1%) were seronegative post-vaccination, with time since vaccination ranging from 5 to 9 years. These seronegative individuals were vaccinated a median of 9.2 years ago, compared to 5.1 years for seropositive participants (P-value = 0.037). Aside from time since vaccination, no other factors (e.g. age, sex) were associated with seronegativity.</p><p><strong>Conclusions: </strong>Imojev® provides durable immunity, with seropositivity exceeding 90% up to 10 years post-vaccination. However, waning immunity in a small proportion of individuals suggests that booster doses may be beneficial for high-risk travellers vaccinated over 5 years ago.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First clinical experiences with the tetravalent live vaccine against dengue (Qdenga®) in travellers: a multicentric TravVacNet study in Germany.","authors":"Clara Köpke, Camilla Rothe, Andreas Zeder, Gerhard Boecken, Torsten Feldt, Christian Janke, Sabine Jordan, Carsten Köhler, Micha Löbermann, Andreas Müller, Hans Martin Orth, Luise Marie Prüfer-Krämer, Johannes Schäfer, Günther Slesak, August Stich, Sabine Bélard, Nico Thul, Sören L Becker, Sophie Schneitler","doi":"10.1093/jtm/taaf004","DOIUrl":"10.1093/jtm/taaf004","url":null,"abstract":"<p><strong>Background: </strong>A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine-related reactions in a predominantly dengue-naïve population, highlighting the importance of post-marketing surveillance as an essential component of safety evaluation for newly licensed vaccines.</p><p><strong>Methods: </strong>Following dengue vaccination, participants were recruited for an anonymous online questionnaire through the national 'Trav VacNet' network in Germany. The questionnaire focused on post-vaccination reactions up to 18 days after the first and second vaccination, as well as previous travel history and coadministration.</p><p><strong>Results: </strong>The study included 1176 participants, with a median age of 39 years (IQR 28-56), 53.2% female (n = 625), 46.5% male (n = 547), and 0.3% non-binary participants (n = 4). After the first dose, 51% of the participants reported systemic reactions such as headache [40% (190/474)], weakness [40% (189/474)], and malaise [32% (154/474)], which were most pronounced between days 7 and 11 post vaccination. After the second dose, localized signs and symptoms such as pain at the injection site [22% (n = 55/250)] were more common. Fever was more common after the first dose [20% (96/474)] vs. 2% (6/250) after the second. Females reported significantly more reactions than males after both vaccinations (1st dose P = 0.0002; 2nd dose P = 0.0003). A total of 334 (28%) co-administrations were reported whereby assessing adverse events were reported in 47% (157/333) of participants, with the highest prevalence observed when combined with the Japanese encephalitis vaccine [56.8%, (42/74)]. Differences in age groups were observed, with a decrease in reactions in the elderly (≥65 years).</p><p><strong>Conclusions: </strong>Vaccine-related reactions were frequently reported, predominantly after the first dose in dengue-naïve participants. Coadministration was a common strategy without significantly increasing side effects. The study provides important insights into reactogenicity and may help improve vaccination strategies in dengue-naïve populations.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}